DBV Technologies | DBVT - Operating Expenses


DBV Technologies reported $37.05M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.48M 113K Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025